All In Biotech

Drug Trial Radar · NCT06978244

A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Actual

Start

Jul 29, 2025

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
May 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Single-Center, Phase 1 study to assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)

Conditions

  • Ocular Pain

Interventions

  • BL1332 ophthalmic solutionDrug

    Both arms taken four times a day for 1 day

  • BL1332 ophthalmic vehicleDrug

    Both arms taken four times a day for 1 day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of DLTs (dose-limiting toxicities)Time frame: Approximately 6 months
  2. Incidence of treatment-emergent AEs (TEAEs)Time frame: Approximately 6 months
  3. Treatment-emergent changes in systemic and ocular safety assessmentsTime frame: Approximately 6 months
  4. PK profiles and following parameter, where data allow (Cmax)Time frame: Approximately 6 months
  5. PK profiles and following parameter, where data allow ( Tmax)Time frame: Approximately 6 months
  6. PK profiles and following parameter, where data allow (Ctau)Time frame: Approximately 6 months
  7. PK profiles and following parameter, where data allow (Tlast)Time frame: Approximately 6 months
  8. PK profiles and following parameter, where data allow ( AUClast)Time frame: Approximately 6 months
  9. PK profiles and following parameter, where data allow (AUCtau)Time frame: Approximately 6 months
  10. PK profiles and following parameter, where data allow (AUCinf)Time frame: Approximately 6 months
  11. PK profiles and following parameter, where data allow (ke1)Time frame: Approximately 6 months
  12. PK profiles and following parameter, where data allow (t1/2)Time frame: Approximately 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site 101

    Fair Lawn, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.